TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

DARAPRIM

PYRIMETHAMINE Dihydrofolate Reductase Inhibitors
Approved 1953-01-23
1
Indication
--
Phase 3 Trials
1
Priority Reviews
73
Years on Market

Details

Status
Prescription
First Approved
1953-01-23
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: PYRIMETHAMINE

DARAPRIM Approval History

Loading approval history...

What DARAPRIM Treats

1 indications

DARAPRIM is approved for 1 conditions since its original approval in 1953. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Toxoplasmosis
Source: FDA Label

Drugs Similar to DARAPRIM

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DARAPRIM FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Treatment of Toxoplasmosis: DARAPRIM is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.